Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,605 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Parmar A, Dai WF, Dionne F, Geirnaert M, Denburg A, Ahuja T, Beca J, Bouchard S, Chambers C, Hunt MJ, Husereau D, Lungu E, McDonald V, Mercer RE, Mitera G, Muñoz C, Naipaul R, Peacock S, Potashnik T, Tadrous M, Takhar P, Taylor M, Trudeau M, Wasney D, Gavura S, Chan KKW. Parmar A, et al. Among authors: chambers c. Curr Oncol. 2023 Mar 28;30(4):3776-3786. doi: 10.3390/curroncol30040286. Curr Oncol. 2023. PMID: 37185399 Free PMC article.
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ; Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group. Mittmann N, et al. J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92. doi: 10.1093/jnci/djp232. Epub 2009 Aug 7. J Natl Cancer Inst. 2009. PMID: 19666851
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group.
Dai WF, Arciero V, Craig E, Fraser B, Arias J, Boehm D, Bosnic N, Caetano P, Chambers C, Jones B, Lungu E, Mitera G, Potashnik T, Reiman A, Ritcher T, Beca JM, Denburg A, Mercer RE, Parmar A, Tadrous M, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration Reassessment And Uptake Working Group. Dai WF, et al. Among authors: chambers c. Curr Oncol. 2021 Oct 16;28(5):4174-4183. doi: 10.3390/curroncol28050354. Curr Oncol. 2021. PMID: 34677272 Free PMC article.
Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Takhar P, Geirnaert M, Gavura S, Beca J, Mercer RE, Denburg A, Muñoz C, Tadrous M, Parmar A, Dionne F, Boehm D, Chambers C, Craig E, Trudeau M, Cheung MC, Houlihan J, McDonald V, Pechlivanoglou P, Taylor M, Wasylenko E, Wranik WD, Chan KKW. Takhar P, et al. Among authors: chambers c. Curr Oncol. 2024 Apr 1;31(4):1876-1898. doi: 10.3390/curroncol31040141. Curr Oncol. 2024. PMID: 38668044 Free PMC article.
1,605 results